Anuh Pharma Limited has received a tax demand and penalty order of ₹17.46 lakhs for Assessment Year 2020-21 from the Income Tax Department. The order was issued under Section 156 and Section 270 of the Income Tax Act, 1961, following a scrutiny assessment. The company stated that the demand arises from disallowances of certain deductions claimed under various provisions of the Income Tax Act.

The order was received by the company on June 18, 2026. The total demand of ₹17.46 lakhs includes a penalty under Section 270A(9) read with Section 270A(8) of the Income Tax Act.

Company Response

Anuh Pharma disclosed that it is in the process of filing an appeal before the Higher Appellate Forums against the said order within the prescribed timelines. The management believes it has adequate factual and legal grounds to substantiate its position in the matter.

The company further stated that, based on its assessment, there is no impact on the financial operations or other activities of the company. The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Details of the Order

Anuh Pharma Limited reported a 16.65% year-on-year increase in revenue from operations to ₹771.66 crore for the financial year ended March 31, 2026. The company successfully completed USFDA and EU GMP inspections during the year, reinforcing its commitment to global quality standards. Despite the revenue growth, net profit for the year declined by 13.32% to ₹41.05 crore, impacted by increased expenses and other income fluctuations.

For the quarter ended March 31, 2026, revenue stood at ₹202.12 crore, compared to ₹197.18 crore in the preceding quarter. The company achieved record production volumes of 1,733 metric tonnes in FY26, an increase of 24.99%, supported by strong plant utilization. EBITDA for the year was ₹66.08 crore, with a margin of 8.56%, while quarterly EBITDA improved to ₹18.63 crore with a margin of 9.22%.

Financial Performance

The following table outlines the key financial metrics for the quarter and full year:

Operational Highlights

The company derived approximately 46% of its revenues from exports in FY26, serving 360 customers across over 72 countries, including Europe, Mexico, and South Africa. Anuh Pharma is one of the largest manufacturers of Macrolides and Anti-TB products in India. The company enhanced its production capacity from 2,200 MTPA to 2,400 MTPA in 2025. Management anticipates a steady growth rate of 15-20% per annum driven by volume expansions and strategic market diversification.